Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2007

View Archived Issues

Novartis discovers a potent NPM-ALK kinase inhibitor

Hivenyl significantly reduces atopic dermatitis itch severity without sedation

VASTox joins European consortium to research new treatments for cancer

Pivotal study evaluates Aastrom's TRCs for osteonecrosis of the femoral head

Cervarix compared to Gardasil in new phase III study

Archemix and Merck KGaA sign aptamer agreement in cancer

FDA grants orphan drug status to VQD-001 for cutaneous leishmaniasis

Two phase I trials cleared to begin for Lymphoseek in prostate and colon cancers

Positive preclinical results with Endocyte's folate receptor-targeted immunotherapy

Lipsovir cold sore program makes progress

1207 shows no clear anesthetic effect in phase I study

Butyrylcholinesterase studied as chemical defense product in new phase I trial

Adherex acquires GSK's options to eniluracil

Enrollment completed in study of AZ-004 in agitated schizophrenic patients

Data on nitroflurbiprofen sets stage for clinical trials in DMD

Neuroprotection by humanin and one of its derivatives: an update

INNO-406 found effective in animal models of CNS Ph+ leukemia

Alimta launched in Japan for malignant pleural mesothelioma

Cipralex approved in Europe for OC

Full European approval for Sutent in advanced renal cell carcinoma

New therapeutic agents for ocular disorders disclosed in recent patent literature

Recent patents report novel analgesic agents

New agents for treating gastrointestinal disorders disclosed in recent patents

Inovelon approved in E.U. for Lennox-Gastaut syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...